Resveratrol attenuates diabetic nephropathy via modulating angiogenesis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Wen, Donghai ^a   Huang, Xinzhong ^a   Zhang, Min ^a   Zhang, Liying ^a   Chen, Jing ^a   Gu, Yong ^a   Hao, Chuan Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CREATININE; RESVERATROL; SIRTUIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS MODULATOR; SIRT1 PROTEIN, RAT; STILBENE DERIVATIVE; VASCULOTROPIN A;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; ENDOTHELIUM CELL; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY MASS; MESANGIUM; NONHUMAN; PODOCYTE; RAT; UPREGULATION; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; MALE; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT;

ANGIOGENESIS MODULATING AGENTS; ANGIOPOIETIN-2; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TIE-2; SIRTUIN 1; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891621483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082336     Document Type: Article

References (54)

1. US Renal Data System (2010) USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Valmadrid CT, Klein R, Moss SE, Klein BE (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 160: 1093-1100. doi:10.1001/archinte.160.8.1093. PubMed: 10789601.
3. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433-2446. doi:10.1056/NEJMoa0708379. PubMed: 18525041.
4. Pichler RH, de Boer IH (2010) Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease. Curr Diab Rep 10: 297-305. doi:10.1007/s11892-010-0126-2. PubMed: 20532701.
5. Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4: 444-452. doi:10.1038/ ncpendmet0894. PubMed: 18607402.
6. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA (2009) Abnormal angiogenesis in diabetic nephropathy. Diabetes 58: 1471-1478. doi:10.2337/db09-0119. PubMed: 19564458.
7. Osterby R, Asplund J, Bangstad HJ, Nyberg G, Rudberg S et al. (1999) Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14: 348-352. doi:10.1093/ndt/14.2.348. PubMed: 10069187.
8. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T et al. (2005) Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45: 288-294. doi:10.1053/j.ajkd.2004.09.020. PubMed: 15685506.
9. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ et al. (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239. doi:10.2337/diabetes.48.11.2229. PubMed: 10535459.
10. Ferrara N (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55: 15-35; discussion:
11. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437: 497-504. doi: 10.1038/nature03987. PubMed: 16177780.
12. Scheppke L, Aguilar E, Gariano RF, Jacobson R, Hood J et al. (2008) Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 118: 2337-2346. PubMed: 18483622.
13. Kang DH, Johnson RJ (2003) Vascular endothelial growth factor :a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 12: 43-49. doi:10.1097/00041552-200301000-00008. PubMed: 12496665.
14. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W et al. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000. PubMed: 11316858.
15. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG et al. (2002) Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094. doi:10.2337/diabetes.51.10.3090. PubMed: 12351452.
16. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS et al. (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17: 3093-3104. doi: 10.1681/ASN.2006010064. PubMed: 16988063.
17. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y et al. (2004) Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840. doi:10.2337/diabetes.53.7.1831. PubMed: 15220208.
18. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y et al. (2005) Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54: 2891-2903. doi:10.2337/diabetes.54.10.2891. PubMed: 16186390.
19. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R et al. (2006) Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 17: 475-486. doi:10.1681/ASN.2005020217. PubMed: 16394111.
20. Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K et al. (2006) 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 55: 1232-1242. doi:10.2337/db05-1367. PubMed: 16644677.
21. Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K et al. (2009) Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes 58: 2365-2375. doi:10.2337/db08-1790. PubMed: 19587360.
22. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K et al. (2011) Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 300: F873-F886. doi:10.1152/ajprenal.00503.2010. PubMed: 21228103.
23. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180. doi:10.1016/S0092-8674(00)81813-9. PubMed: 8980224.
24. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60. doi:10.1126/science.277.5322.55. PubMed: 9204896.
25. Visconti RP, Richardson CD, Sato TN (2002) Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 99: 8219-8224. doi:10.1073/pnas. 122109599. PubMed: 12048246.
26. Woolf AS, Yuan HT (2001) Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 16: 177-184. doi:10.1007/s004670000509. PubMed: 11261688.
27. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A (2002) Plant foods and herbal sources of resveratrol. J Agric Food Chem 50: 3337-3340. doi:10.1021/jf0112973. PubMed: 12010007.
28. Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L et al. (2007) Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 43(5): 720-729. doi:10.1016/j.freeradbiomed.2007.05.004. PubMed: 17664136.
29. Tang Z, Liu XY, Zou P (2007) Resveratrol inhibits the secretion of vascular endothelial growth factor and subsequent proliferation in human leukemia U937 cells. J Huazhong Univ Sci Technolog Med Sci 27: 508-512. doi:10.1007/s11596-007-0508-0. PubMed: 18060622.
30. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J et al. (2005) Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1474. doi: 10.1158/1535-7163.MCT-05-0198. PubMed: 16227395.
31. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS et al. (2007) Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett 258: 63-69. doi:10.1016/j.canlet.2007.08.011. PubMed: 17919812.
32. Hu Y, Sun CY, Huang J, Hong L, Zhang L et al. (2007) Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl) 120: 1672-1677. PubMed: 17935668.
33. Lin MT, Yen ML, Lin CY, Kuo ML (2003) Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64: 1029-1036. doi:10.1124/mol.64.5.1029. PubMed: 14573751.
34. Alex D, Leong EC, Zhang ZJ, Yan GT, Cheng SH et al. (2010) Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cell Biochem 109: 339-346. PubMed: 20014068.
35. Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231: 113-122. doi:10.1016/j.canlet.2005.01.031. PubMed: 16356836.
36. Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D et al. (2010) Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 70: 7392-7399. doi: 10.1158/0008-5472.CAN-10-2027. PubMed: 20841478.
37. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M et al. (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011. doi: 10.1158/0008-5472.CAN-10-2364. PubMed: 20935227.
38. Liang F, Kume S, Koya D (2009) SIRT1 and insulin resistance. Nat Rev Endocrinol 5: 367-373. doi:10.1038/nrendo.2009.101. PubMed: 19455179.
39. Feige JN, Auwerx J (2008) Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol 20: 303-309. doi:10.1016/j.ceb.2008.03.012. PubMed: 18468877.
40. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13. doi:10.1042/BJ20070420. PubMed: 17447894.
41. He W, Wang Y, Zhang MZ, You L, Davis LS et al. (2010) Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 120: 1056-1068. doi:10.1172/JCI41563. PubMed: 20335659.
42. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y et al. (2010) Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem 285: 13045-13056. doi:10.1074/jbc.M109.067728. PubMed: 20139070.
43. Lim JH, Lee YM, Chun YS, Chen J, Kim JE et al. (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38: 864-878. doi:10.1016/j.molcel.2010.05.023. PubMed: 20620956.
44. Mundel P, Reiser J, Mejia Borja Zuniga A, Pavenstadt H, Davidson GR et al. (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258. doi:10.1006/excr.1997.3739. PubMed: 9344605. Available online at: doi:10.1006/excr.1997.3739 Available online at: PubMed: 9344605
45. Wen D, You L, Zhang Q, Zhang L, Gu Y et al. (2011) Upregulation of nestin protects podocytes from apoptosis induced by puromycin aminonucleoside. Am J Nephrol 34(5): 423-434. doi: 10.1159/000331701. PubMed: 21952051.
46. Akis N, Madaio MP (2004) Isolation, culture, and characterization of endothelial cells from mouse glomeruli. Kidney Int 65: 2223-2227. doi: 10.1111/j.1523-1755.2004.00634.x. PubMed: 15149335.
47. Nemoto S, Fergusson MM, Finkel T (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280: 16456-16460. doi:10.1074/jbc.M501485200. PubMed: 15716268.
48. Wen D, Ni L, You L, Zhang L, Gu Y et al. (2012) Upregulation of nestin in proximal tubules may participate in cell migration during renal repair. Am J Physiol Renal Physiol 303(11): F1534-F1544. doi:10.1152/ajprenal.00083.2012. PubMed: 22993065.
49. Chen J, Boyle S, Zhao M, Su W, Takahashi K et al. (2006) Differential expression of the intermediate filament protein nestin during renal development and its localization in adult podocytes. J Am Soc Nephrol 17: 1283-1291. doi:10.1681/ASN.2005101032. PubMed: 16571784.
50. Kalluri R, Sukhatme VP (2000) Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 9: 413-418. doi: 10.1097/00041552-200007000-00013. PubMed: 10926178.
51. Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T et al. (2002) Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160: 1683-1693. doi:10.1016/S0002-9440(10)61115-7. PubMed: 12000720.
52. Tong Q, Zheng L, Lin L, Li B, Wang D et al. (2006) Participation of the PI-3K/Akt-NF-kappa B signaling pathways in hypoxia-induced mitogenic factor-stimulated Flk-1 expression in endothelial cells. Respir Res 7: 101. doi:10.1186/1465-9921-7-101. PubMed: 16872509.
53. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380. doi:10.1038/sj.emboj.7600244. PubMed: 15152190.
54. Kim MY, Lim JH, Youn HH, Hong YA, Yang KS et al. (2013) Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axisin db/db mice. Diabetologia 56(1): 204-217. doi:10.1007/s00125-012-2747-2. PubMed: 23090186.